| Assessment Status | Rapid Review Complete |
| HTA ID | 25008 |
| Drug | Lebrikizumab |
| Brand | Ebglyss® |
| Indication | Lebrikizumab (Ebglyss®) is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40kg who are candidates for systemic therapy. |
| Assessment Process | |
| Rapid review commissioned | 05/02/2025 |
| Rapid review completed | 19/02/2025 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of lebrikizumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
